These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 27770107)

  • 1. Is It Adverse, Nonadverse, Adaptive, or Artifact?
    Pandiri AR; Kerlin RL; Mann PC; Everds NE; Sharma AK; Myers LP; Steinbach TJ
    Toxicol Pathol; 2017 Jan; 45(1):238-247. PubMed ID: 27770107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicologic Pathology Forum*: Commentary on "Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma".
    Patrick DJ; Troth SP
    Toxicol Pathol; 2019 Jul; 47(5):574-576. PubMed ID: 31303126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies.
    Keirstead ND; Janovitz EB; Meehan JT; LeRoy BE; Megill JR; Peterson RA; Masson RG; Marxfeld HA
    Toxicol Pathol; 2019 Jun; 47(4):461-468. PubMed ID: 31018785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Society of Toxicologic Pathology position paper on best practices on recovery studies: the role of the anatomic pathologist.
    Perry R; Farris G; Bienvenu JG; Dean C; Foley G; Mahrt C; Short B;
    Toxicol Pathol; 2013; 41(8):1159-69. PubMed ID: 23531793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicologic Pathology Forum*: Opinion on Designation of Adverse and Nonadverse Histopathological Findings in Toxicity Studies: The Pathologist's Dilemma.
    Gopinath C; Mowat V
    Toxicol Pathol; 2019 Jul; 47(5):564-573. PubMed ID: 31291835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response letter from Clinical Pathology Interest Group of the Society of Toxicologic Pathology (STP) for manuscript entitled International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies by Bolon et al.
    Tripathi NK; Schultze AE; Pearson RC; Everds NE; Elliott GS; Ramaiah L; Wells MY; Latimer KS; Walter GL; Katavolos P; Collins ND; Tarrant J; Walker DB; Topper MJ; Jordan HL; O'Rourke LG; Guilpin VB; Brockus CW; Wilcox AL; Clemo FA; Smith GS; Reagan WJ; McCartney JE
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):39. PubMed ID: 21676604
    [No Abstract]   [Full Text] [Related]  

  • 7. Scientific and Regulatory Policy Committee: Recommended ("Best") Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies.
    Kerlin R; Bolon B; Burkhardt J; Francke S; Greaves P; Meador V; Popp J
    Toxicol Pathol; 2016 Feb; 44(2):147-62. PubMed ID: 26704930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles for Assessing Adversity in Toxicologic Clinical Pathology.
    Ramaiah L; Tomlinson L; Tripathi NK; Cregar LC; Vitsky A; Beust BV; Barlow VG; Reagan WJ; Ennulat D
    Toxicol Pathol; 2017 Feb; 45(2):260-266. PubMed ID: 28056663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicologic Pathology Forum Opinion Paper*: Recommendations for a Tiered Approach to Nonclinical Mechanistic Nephrotoxicity Evaluation.
    Ennulat D; Ringenberg M; Frazier KS
    Toxicol Pathol; 2018 Aug; 46(6):636-646. PubMed ID: 30049250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Brief Overview of the STP 35th Annual Symposium on the Basis and Relevance of Variation in Toxicologic Responses.
    Irizarry AR; Gropp KE; Dixon D
    Toxicol Pathol; 2017 Jan; 45(1):52-56. PubMed ID: 27815490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development.
    Halpern WG; Ameri M; Bowman CJ; Elwell MR; Mirsky ML; Oliver J; Regan KS; Remick AK; Sutherland VL; Thompson KE; Tremblay C; Yoshida M; Tomlinson L
    Toxicol Pathol; 2016 Aug; 44(6):789-809. PubMed ID: 27235322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.
    McDorman KS; Bennet BM; Colman K; Fikes JD; Keirstead ND; Lanning Retired L; Munch B; Romeike A; Schafer KA; Schorsch F; Thibodeau MS; Thomas HC; Troth S; Vahle JL; Geoly FJ
    Toxicol Pathol; 2024 Feb; 52(2-3):138-148. PubMed ID: 38840532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop.
    Palazzi X; Burkhardt JE; Caplain H; Dellarco V; Fant P; Foster JR; Francke S; Germann P; Gröters S; Harada T; Harleman J; Inui K; Kaufmann W; Lenz B; Nagai H; Pohlmeyer-Esch G; Schulte A; Skydsgaard M; Tomlinson L; Wood CE; Yoshida M
    Toxicol Pathol; 2016 Aug; 44(6):810-24. PubMed ID: 27102650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. International recommendations for training future toxicologic pathologists participating in regulatory-type, nonclinical toxicity studies.
    Bolon B; Barale-Thomas E; Bradley A; Ettlin RA; Franchi CA; George C; Giusti AM; Hall R; Jacobsen M; Konishi Y; Ledieu D; Morton D; Park JH; Scudamore CL; Tsuda H; Vijayasarathi SK; Wijnands MV
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):187-95. PubMed ID: 20724123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Trends of Practices in Nonclinical Toxicology: An Industry Survey.
    Authier S; Brock WJ; Halpern W; Harris SN; Jones D; McGovern T; McGovern PD; Pugsley MK
    Int J Toxicol; 2021 Dec; 40(6):487-505. PubMed ID: 34569357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicologic Pathology Forum*: Opinion on Sexual Maturity and Fertility Assessment in Long-tailed Macaques ( Macaca fascicularis) in Nonclinical Safety Studies.
    Mecklenburg L; Luetjens CM; Weinbauer GF
    Toxicol Pathol; 2019 Jun; 47(4):444-460. PubMed ID: 30898082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Standard for the Exchange of Nonclinical Data (SEND): Challenges and Promises.
    Choudhary S; Walker A; Funk K; Keenan C; Khan I; Maratea K
    Toxicol Pathol; 2018 Dec; 46(8):1006-1012. PubMed ID: 30295163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Considerations in Determining Adversity and the No-Observed-Adverse-Effect-Level (NOAEL) in Nonclinical Safety Studies: Challenges, Perspectives and Case Studies.
    Kale VP; Bebenek I; Ghantous H; Kapeghian J; Singh BP; Thomas LJ
    Int J Toxicol; 2022; 41(2):143-162. PubMed ID: 35230174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interpreting and Integrating Clinical and Anatomic Pathology Results.
    Ramaiah L; Hinrichs MJ; Skuba EV; Iverson WO; Ennulat D
    Toxicol Pathol; 2017 Jan; 45(1):223-237. PubMed ID: 27879439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
    Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
    Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.